Petros Pharmaceuticals, Inc.
PTPI
$0.01
$0.001.41%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 299.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 299.12% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.22% | -17.26% | 33.48% | -2.97% | -79.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.22% | -17.26% | 33.48% | -2.97% | -87.64% |
| Operating Income | 32.22% | 17.26% | -33.48% | 2.97% | 88.54% |
| Income Before Tax | 39.13% | -0.35% | -631.17% | -413.27% | -273.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.13% | -0.35% | -631.17% | -413.27% | -273.73% |
| Earnings from Discontinued Operations | 100.00% | -- | 814.34% | 58.34% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 96.37% | 58.45% | 920.66% | -4.50% | -3,014.33% |
| EBIT | 32.22% | 17.26% | -33.48% | 2.97% | 88.54% |
| EBITDA | 302.93% | 38.22% | -73.13% | 4.41% | 101.85% |
| EPS Basic | 100.16% | 99.80% | 86.05% | 77.78% | 33.91% |
| Normalized Basic EPS | 99.41% | 99.07% | -106.05% | -151.31% | -140.87% |
| EPS Diluted | 100.16% | 99.80% | 86.05% | 77.78% | 33.91% |
| Normalized Diluted EPS | 99.41% | 99.07% | -106.05% | -151.31% | -140.87% |
| Average Basic Shares Outstanding | 10,397.35% | 10,653.94% | 8,672.42% | 510.51% | 325.13% |
| Average Diluted Shares Outstanding | 10,397.35% | 10,653.94% | 8,672.42% | 510.51% | 325.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |